KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Assets (2016 - 2025)

Thermo Fisher Scientific's Assets history spans 17 years, with the latest figure at $110.3 billion for Q4 2025.

  • For the quarter ending Q4 2025, Assets rose 13.38% year-over-year to $110.3 billion, compared with a TTM value of $110.3 billion through Dec 2025, up 13.38%, and an annual FY2025 reading of $110.3 billion, up 13.38% over the prior year.
  • Assets for Q4 2025 was $110.3 billion at Thermo Fisher Scientific, up from $103.0 billion in the prior quarter.
  • The five-year high for Assets was $110.3 billion in Q4 2025, with the low at $65.9 billion in Q2 2021.
  • Average Assets over 5 years is $93.2 billion, with a median of $97.1 billion recorded in 2023.
  • Year-over-year, Assets skyrocketed 40.67% in 2022 and then decreased 1.42% in 2024.
  • Tracing TMO's Assets over 5 years: stood at $95.1 billion in 2021, then increased by 2.14% to $97.2 billion in 2022, then grew by 1.62% to $98.7 billion in 2023, then dropped by 1.42% to $97.3 billion in 2024, then increased by 13.38% to $110.3 billion in 2025.
  • Per Business Quant, the three most recent readings for TMO's Assets are $110.3 billion (Q4 2025), $103.0 billion (Q3 2025), and $101.2 billion (Q2 2025).